Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma

June 22, 2011 By Bio-Medicine.Org

VIENNA, June 22, 2011 /PRNewswire/ —

 

Vienna based biotech company APEIRON Biologics AG (Apeiron)
strengthens its oncology pipeline: The company will support the
clinical development of an immune therapy against high-risk
neuroblastoma that is being conducted by the
Children
‘s Cancer Research Institute (CCRI) and the
European Neuroblastoma Research Network (SIOPEN). It is presently
under investigation in a phase III trial across various European
clinical centers. In return, Apeiron obtains the rights to file for
regulatory approval and to market the final product. The approach
is based on a monoclonal antibody (ch14.18) and constitutes
Apeiron
‘s most advanced project. It also marks
another milestone for the company and its development strategy to
treat neuroblastoma. This strategy was initiated earlier this year
with the licensing of a clinical phase II project from Merck
KGaA.

Today, Vienna based Apeiron announced the conclusion of an
agreement with the Children’s Cancer Research Institute (CCRI) and
the European Neuroblastoma Research Network (SIOPEN). Thereby,
Apeiron obtains the rights to further develop, file for regulatory
approval and market the antibody ch14.18. This monoclonal antibody
exhibits therapeutic effect against high-risk neuroblastoma, an
aggressive form of infant cancer. The antibody specifically targets
the antigen GD2, a feature on the surface of neuroblastoma cells
and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial
support for an ongoing European clinical phase III trial with
ch14.18. Due to the limited number of clinical centers specializing
in the treatment of high-risk neuroblastoma, Apeiron is considering
marketing the therapy on its own.

The Austrian company Polymun Scientific, a long-time business
partner of Apeiron, has already been producing clinical supplies
for the CCRI/SIOPEN spo

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech